| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BCPT.12341 |
| P698 | PubMed publication ID | 25348905 |
| P2093 | author name string | In-Wha Kim | |
| Jung Mi Oh | |||
| Nayoung Han | |||
| Minji Sohn | |||
| Eui-Kyung Lee | |||
| Eunhee Ji | |||
| Therasa Kim | |||
| P2860 | cites work | Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 |
| DrugBank 4.0: shedding new light on drug metabolism | Q24568341 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| Redundancy control in pathway databases (ReCiPa): an application for improving gene-set enrichment analysis in Omics studies and "Big data" biology. | Q30646165 | ||
| Developmental pharmacology--drug disposition, action, and therapy in infants and children | Q34247047 | ||
| The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes | Q34502898 | ||
| Developmental and pediatric pharmacogenomics | Q35116112 | ||
| Pharmacogenomics and children: meeting the ethical challenges | Q35606641 | ||
| Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond | Q35808788 | ||
| Pharmacogenomics of acute leukemia. | Q36364686 | ||
| Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations | Q36544972 | ||
| Pharmacogenetics and pharmacogenomics: development, science, and translation | Q36583761 | ||
| Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations | Q36627208 | ||
| Pharmacogenomics and adverse drug reactions in children. | Q37719025 | ||
| Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. | Q37808658 | ||
| The status of paediatric medicines initiatives around the world--What has happened and what has not? | Q37898039 | ||
| Pediatric perspective on pharmacogenomics. | Q38162869 | ||
| Physiologic Hyperbilirubinemia in the Neonatal Period | Q40050240 | ||
| New feature: pathways and important genes from PharmGKB | Q42000552 | ||
| Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. | Q50707361 | ||
| P433 | issue | 5 | |
| P921 | main subject | biomarker | Q864574 |
| pharmacogenomics | Q1152227 | ||
| P304 | page(s) | 438-444 | |
| P577 | publication date | 2014-11-21 | |
| P1433 | published in | Basic and Clinical Pharmacology and Toxicology | Q15724438 |
| P1476 | title | Pharmacogenomic biomarker information in FDA-approved paediatric drug labels | |
| P478 | volume | 116 |
| Q38879907 | Design and conduct of early phase drug studies in children: challenges and opportunities |
| Q38547448 | Histamine-2 Receptor Antagonists and Semen Quality |
| Q90208079 | International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States |
| Q91582436 | Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view |
| Q40181637 | Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients |
Search more.